|
🐜
|
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
17 auth.
S. Tolaney,
A. Wardley,
S. Zambelli,
J. Hilton,
T. Troso-Sandoval,
F. Ricci,
S. Im,
Sung-Bae Kim,
Stephen R. D. Johnston,
A. Chan,
...
S. Goel,
K. Catron,
Sonya C. Chapman,
G. Price,
Zhengyu Yang,
M. C. Gainford,
F. André
|
7 |
2020 |
7
🐜
|
|
🐜
|
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
16 auth.
S. Tolaney,
S. Sahebjam,
É. Le Rhun,
T. Bachelot,
P. Kabos,
A. Awada,
D. Yardley,
A. Chan,
P. Conte,
V. Diéras,
...
N. Lin,
M. Bear,
Sonya C. Chapman,
Zhengyu Yang,
Yanyun Chen,
C. Anders
|
6 |
2020 |
6
🐜
|
|
🐜
|
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
12 auth.
H. Rugo,
P. Kabos,
J. Beck,
G. Jerusalem,
H. Wildiers,
E. Sevillano,
...
L. Paz-Ares,
M. Chisamore,
Sonya C. Chapman,
A. Hossain,
Yanyun Chen,
S. Tolaney
|
5 |
2022 |
5
🐜
|
|
🐜
|
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
30 auth.
K. Autio,
C. Klebanoff,
David A. Schaer,
J. Kauh,
S. Slovin,
Matthew Adamow,
V. Blinder,
M. Brahmachary,
Michelle Carlsen,
E. Comen,
D. Danila,
T. Doman,
J. Durack,
J. Fox,
J. Gluskin,
...
D. Hoffman,
Suhyun Kang,
Praneet Kang,
Jonathan Landa,
P. McAndrew,
S. Modi,
M. Morris,
R. Novosiadly,
D. Rathkopf,
R. Sanford,
Sonya C. Chapman,
C. Tate,
Danni Yu,
P. Wong,
H. McArthur
|
5 |
2020 |
5
🐜
|
|
🐜
|
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
16 auth.
G. Falchook,
M. Peeters,
S. Rottey,
L. Dirix,
R. Obermannova,
J. Cohen,
Ruth Perets,
R. S. Frommer,
T. Bauer,
Judy S. Wang,
...
R. Carvajal,
J. Sabari,
Sonya C. Chapman,
Wei Zhang,
B. Calderon,
D. Peterson
|
5 |
2021 |
5
🐜
|
|
🐜
|
Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
46 auth.
Jian Du,
Lei Yan,
R. Torres,
Xueqian Gong,
H. Bian,
C. Marugán,
K. Boehnke,
Carmen Baquero,
Y. Hui,
Sonya C. Chapman,
Yanzhu Yang,
Yi-Fei Zeng,
Sarah M. Bogner,
R. Foreman,
A. Capen,
...
Gregory P. Donoho,
R. V. Van Horn,
D. Barnard,
J. Dempsey,
R. Beckmann,
M. Marshall,
L. Chio,
Y. Qian,
Y. Webster,
A. Aggarwal,
S. Chu,
Shobha N. Bhattachar,
L. Stancato,
M. Dowless,
P. Iversen,
J. Manro,
Jennie L. Walgren,
B. Halstead,
M. Z. Dieter,
R. Martinez,
S. Bhagwat,
E. Kreklau,
M. Lallena,
X. Ye,
Bharvin Patel,
C. Reinhard,
G. Plowman,
D. Barda,
J. Henry,
S. Buchanan,
R. Campbell
|
5 |
2019 |
5
🐜
|
|
🐜
|
LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial
13 auth.
A. Dowlati,
R. Harvey,
R. Carvajal,
O. Hamid,
S. Klempner,
J. Kauh,
D. Peterson,
Danni Yu,
Sonya C. Chapman,
Anna M. Szpurka,
...
Michelle Carlsen,
T. Quinlan,
R. Wesolowski
|
5 |
2021 |
5
🐜
|
|
🐜
|
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
15 auth.
E. Hamilton,
J. Cortés,
O. Ozyılkan,
Shin-Cheh Chen,
K. Petráková,
A. Manikhas,
G. Jerusalem,
R. Hegg,
J. Huober,
Sonya C. Chapman,
...
Yi Lu,
M. C. Hardebeck,
M. Bear,
E. Johnston,
Miguel Martín
|
4 |
2020 |
4
🐜
|
